We previously reported a
monoclonal antibody named IF-43 that specifically recognizes
thrombin-modified
fibrinogen (desAA- and desAABB-
fibrin monomer) bound with
fibrinogen or other D(1) domain-containing plasmic fragments such as fragments X,Y, and D(1), but not intact
fibrinogen or cross-linked
fibrin degradation products (XDP). Here, we tentatively named such complexes, soluble
fibrin monomer (FM) -
fibrinogen complex. By utilizing IF-43, we have developed a kit to measure soluble FM-
fibrinogen complex and compared the profiles with those of two established molecular markers for thrombo-embolic disorders: i.e. the
thrombin-antithrombin complex (TAT) and the
D-dimer in plasma of patients who underwent surgery without any thrombo-embolic complications. The result indicated that soluble FM-
fibrinogen complex is a distinct entity from the two established molecular markers. We have also attempted to observe their profiles in patients with the
disseminated intravascular coagulation syndrome (
DIC). Although the pro-files of soluble FM-
fibrinogen complex in individual patients appeared to vary from one patient to the other, the plasma level of soluble FM-
fibrinogen complex was found to be increased at the initial phase of
disseminated intravascular coagulation syndrome. Thus, the soluble FM-
fibrinogen complex may serve as an independent molecular marker for the detection of
thrombin generation and the diagnosis of
thrombosis. The soluble FM-
fibrinogen complex may also serve as a risk factor for
thrombosis, because it may precipitate as insoluble complexes beyond its threshold in plasma, or when it is modified by
thrombin.